Skip to main content

Passage BIO, Inc.

PASG
Exchange
Nasdaq
Industry
Biological Products, (No Diagnostic Substances)
SEC CIK
0001787297

No open-market purchases or sales by Passage BIO, Inc. insiders were filed in the last 90 days; 29 institutions reported holding it in 13F filings for Q2 2026, worth $6.82M in total; no superinvestor holds it.

Q2 2026 vs. Q1 2026

How the institutions holding Passage BIO, Inc. changed between Q1 2026 and Q2 2026.

All holders in Q2 2026All holders in Q1 2026

13F holders of PASG: Q1 2026 compared with Q2 2026
MeasureQ1 2026Of which not filed for Q2 2026Q2 2026Change
Holders35129−5
Shares1.78M11.40M−381.9K (−21.5%)
Value$13.8M$8$6.82M−$7.01M (−50.7%)

1 institution that held it in Q1 2026 haven't filed for Q2 2026 yet. Not filing isn't selling, so the changes leave them out.

New holders (4)

Institutions that held Passage BIO, Inc. at the end of Q2 2026 but not at the end of Q1 2026.

Institutions new to PASG in Q2 2026
InstitutionSharesValue% of portfolio
Balyasny Asset Management LLC107,025$522.3K0.00%
Deltec Asset Management LLC15,000$73.2K0.01%
HRT Financial LP12,712$62.0K0.00%
GTS Securities LLC10,000$48.8K0.00%

Sold out (9)

Institutions that held Passage BIO, Inc. at the end of Q1 2026 and filed for Q2 2026 without it.

Institutions that sold out of PASG in Q2 2026
InstitutionShares, Q1 2026Value, Q1 2026
Vestal Point Capital, LP305,000$2.39M
Eversept Partners, LP131,581$1.03M
Diadema Partners LP19,530$153.3K
XTX Topco Ltd12,627$99.1K
Persistent Asset Partners Ltd4,955$38.9K
Rockefeller Capital Management L.P.800$6.28K
Tower Research Capital LLC (TRC)502$3.94K
Parallel Advisors, LLC16$126
Royal Bank of Canada2$0

Not filed for Q2 2026 yet (1)

Institutions that held Passage BIO, Inc. at the end of Q1 2026 and haven't filed a 13F for Q2 2026. Not filing isn't selling, so they aren't counted as sold out.

Institutions holding PASG in Q1 2026 that haven't filed for Q2 2026
InstitutionShares, Q1 2026Value, Q1 2026
CWM, LLC1$8